Precision BioSciences, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Precision BioSciences, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Growth Efficiency Ratio: Sales grew 37% in 3 years; of every extra $100 of sales, $719 became extra profit. Higher than 95% of Healthcare companies in United States.
- Tangible Net Worth Ratio: Of every $100 of net worth, $99 is tangible; the rest is goodwill and other intangibles, often from buying other companies. More tangible than 91% of Healthcare companies in United States.
- Tangible Assets Ratio: Of every $100 the company owns, $99 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles. More tangible than 91% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-64.1×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 76% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
2/3 · 2/3Sales grew in 2 of the last 3 years; profit grew in 2 of 3.
Steadier than 69% of Healthcare companies in United States.
Growth Efficiency Ratio
$719Sales grew 37% in 3 years; of every extra $100 of sales, $719 became extra profit.
Higher than 95% of Healthcare companies in United States.
Asset Productivity Ratio
+37% / -35%In 3 years sales changed by +37% while total assets changed by -35%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
-43.7×Operating cash was negative last year, while some debt falls due within a year.
Lower than 70% of Healthcare companies in United States.
Cash Cushion Ratio
+46%Cash, after subtracting all debt, equals 46% of its market value (net cash).
Higher than 77% of Healthcare companies in United States.
Tangible Assets Ratio
99%Of every $100 the company owns, $99 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 91% of Healthcare companies in United States.
Tangible Net Worth Ratio
99%Of every $100 of net worth, $99 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 91% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
Precision BioSciences, Inc. made a loss over the last year. Precision BioSciences, Inc. owes $0.64 for every $1 it owns. Precision BioSciences, Inc. made a loss in the year to Dec 2025, after a profit the year before.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossPrecision BioSciences, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
4.13The share price is 4.13 times Precision BioSciences, Inc.'s book value per share, higher than 66% of Healthcare companies in United States.
Market cap
$187 MThe total market value of all of Precision BioSciences, Inc.'s shares at today's price (share price × number of shares), smaller than 58% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$45 MWhat Precision BioSciences, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$1.64Net worth divided by the number of shares. The share price of $6.78 is 4.1 times this, which is the P/B above.
Return on equity (ROE)
-135.2%Precision BioSciences, Inc. lost 135.2% of its shareholders' money over the last year, lower than 78% of Healthcare companies in United States.
Owes vs Owns
0.64×Precision BioSciences, Inc. owes $0.64 for every $1 it owns (moderate), higher than 67% of Healthcare companies in United States.
Dividend yield
NonePrecision BioSciences, Inc. does not currently pay a dividend.
Revenue growth
-50%Revenue fell 50% in the year to Dec 2025, and grew 11% a year on average over 3 years.
Profit growth
LossPrecision BioSciences, Inc. made a loss in the year to Dec 2025, after a profit the year before.
Profit margin
-133.4%Precision BioSciences, Inc. lost $133 for every $100 of revenue.
Interest cover
Not coveredPrecision BioSciences, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net cashPrecision BioSciences, Inc. held $87 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Precision BioSciences, Inc.: $187 M ÷ $45 M (30 Jun 2026) = 4.1.
What is Precision BioSciences, Inc.'s return on equity?
Precision BioSciences, Inc. lost 135.2% of its shareholders' money over the last year, lower than 78% of Healthcare companies in United States.
How much does Precision BioSciences, Inc. owe compared with what it owns?
Precision BioSciences, Inc. owes $0.64 for every $1 it owns (moderate), higher than 67% of Healthcare companies in United States.
Does Precision BioSciences, Inc. pay a dividend?
No. Precision BioSciences, Inc. does not currently pay a dividend.
Is Precision BioSciences, Inc.'s revenue growing?
Revenue fell 50% in the year to Dec 2025, and grew 11% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.